Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with 177Lu-D OTATATE

Erratum to: Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with ¹⁷⁷Lu-D OTATATE

Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):352. doi: 10.1007/s00259-016-3558-3.

¹ Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
² Medical Physics Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
³ Radiology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
⁴ Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
⁵ Osteoncology and Rare Tumors Center, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
⁶ Department of Oncology, Verona Comprehensive Cancer Network, G.B. Rossi Hospital, University of Verona, Verona, Italy.
⁷ Division of Nuclear Medicine, European Institute of OncologyMilan (IEO), Milan, Italy.
⁸ Nuclear Medicine Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. giovanni.paganelli@irst.emr.it.

No abstract available